← ANALYST RATINGS · TIPRANKS
Arvinas Holding Company (ARVN): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy5 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $15.09, the highest $21.00, the lowest $8.68. The average is +116.4% from the last price of $6.97.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.00−12.5% | Hold | +0.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $8.00 → $7.50−6.2% | Hold | +7.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.00−12.5% | Hold | +0.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $7.50 → $7.00−6.7% | Hold | +0.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $8.00 → $7.50−6.2% | Hold | +7.6% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 → $7.00−12.5% | Hold | +0.4% | Reiterated | 16.10.26on TipRanks Oct 15 23:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $7.50 → $8.00+6.7% | Hold | +14.8% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $7.50 → $8.00+6.7% | Hold | +14.8% | Reiterated | 10.10.26on TipRanks Oct 9 23:05 | — | |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $12.00 | Hold | +72.2% | Reiterated | 08.10.26on TipRanks 08:35 | +1.2%next day +1.1% · 5 days −4.4% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $8.00 → $7.50−6.2% | Hold | +7.6% | Reiterated | 08.10.26on TipRanks Oct 7 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $8.00 → $7.50−6.2% | Hold | +7.6% | Reiterated | 08.10.26on TipRanks Oct 7 23:05 | — | |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | $16.00 | Hold | +129.6% | Reiterated | 07.10.26on TipRanks Oct 8 05:16 | +2.2%next day +1.2% · 5 days −7.5% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $10.00 → $8.00−20.0% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $10.00 → $8.00−20.0% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $10.00 → $8.00−20.0% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $9.50 → $7.50−21.1% | Hold | +7.6% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $10.00 → $8.00−20.0% | Hold | +14.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $8.00 | Hold | +14.8% | Reiterated | 30.09.26on TipRanks Sep 29 23:05 | — | |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $10.00 → $20.00+100.0% | Buy | +186.9% | Reiterated | 14.09.26on TipRanks 08:15 | −0.1%next day −1.2% · 5 days −3.1% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $11.00 → $10.00−9.1% | Hold | +43.5% | Assigned | 10.08.26on TipRanks 08:20 | +2.8%next day +0.3% · 5 days +2.4% | ↗ |
| Jonathan Miller★★★★★★★★★★#10361 · hits 41% · avg −3.3% | Evercore ISI | $19.00 → $14.00−26.3% | Buy | +100.9% | Assigned | 10.08.26on TipRanks 08:20 | +2.8%next day +0.3% · 5 days +2.4% | ↗ |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $8.68 | Hold | +24.5% | Assigned | 10.08.26on TipRanks 08:07 | +2.8%next day +0.3% · 5 days +2.4% | ↗ |
| Yigal Nochomovitz★★★★★★★★★★#616 · hits 51% · avg +15.1% | Citi | $24.00 → $21.00−12.5% | Buy | +201.3% | Reiterated | 10.08.26on TipRanks 06:55 | +2.8%next day +0.3% · 5 days +2.4% | ↗ |
| Tazeen Ahmad★★★★★★★★★★#1537 · hits 60% · avg +5.8% | Bank of America Securities | — | Hold | — | Reiterated | 07.08.26on TipRanks 15:35 | +0.2%next day +2.8% · 5 days +2.1% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $18.00 | Buy | +158.2% | Reiterated | 05.08.26on TipRanks 13:35 | −6.5%next day +3.5% · 5 days +5.2% | ↗ |
| Robert Driscoll★★★★★★★★★★#1346 · hits 46% · avg +10.6% | Wedbush | $11.00 → $12.00+9.1% | Hold | +72.2% | Reiterated | 05.08.26on TipRanks 08:10 | −6.5%next day +3.5% · 5 days +5.2% | ↗ |
| Etzer Darout★★★★★★★★★★#105 · hits 63% · avg +31.4% | Barclays | $20.00 | Buy | +186.9% | Reiterated | 05.08.26on TipRanks 04:13 | −6.5%next day +3.5% · 5 days +5.2% | ↗ |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $15.00 → $11.00−26.7% | Hold | +57.8% | Downgrade | 05.08.26on TipRanks Aug 4 13:27 | +9.9%next day −6.5% · 5 days 0.0% | ↗ |
| Nicholas Lorusso★★★★★★★★★★#2971 · hits 56% · avg +39.7% | TD Cowen | — | Hold | — | Reiterated | 04.08.26on TipRanks Aug 5 02:50 | +9.9%next day −6.5% · 5 days 0.0% | ↗ |
| Unknown Analyst | Leerink Partners | $18.00 → $9.00−50.0% | Hold | +29.1% | Reiterated | 15.05.26on TipRanks May 22 04:45 | −2.4%next day −3.2% · 5 days −0.8% | |
| Jeet Mukherjee★★★★★★★★★★#655 · hits 63% · avg +26.2% | BTIG | $16.00 → $18.00+12.5% | Buy | +158.2% | Reiterated | 13.05.26on TipRanks 07:30 | +2.6%next day −5.3% · 5 days −7.7% | ↗ |
| Paul Choi★★★★★★★★★★#1415 · hits 56% · avg +9.6% | Goldman Sachs | $6.00 | Sell | −13.9% | Reiterated | 12.05.26on TipRanks May 13 08:30 | −0.8%next day +2.6% · 5 days −10.1% | ↗ |
| Sudan Loganathan★★★★★★★★★★#1955 · hits 65% · avg +22.0% | Stephens | $18.00 | Buy | +158.2% | Reiterated | 25.02.26on TipRanks 08:35 | +6.6%next day +1.2% · 5 days +4.7% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Arvinas Holding Company
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $14.96 at a price of $7.74 (+93.5%); now: $15.07 at $6.97 (+116.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 13 | 13 | 12 | 6 | 5 | 5 |
| Buy | 5 | 1 | 1 | 0 | 0 | 0 |
| Hold | 6 | 3 | 4 | 6 | 6 | 6 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 10.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.87 (from $-1.20 to $-0.09). Last quarter: $2.58.
Sales
Next quarter’s sales estimate — $17M (from $0M to $73M). Last quarter: $250M.
Best top-analyst consensus in the sector · Healthcare
About Arvinas Holding Company
- CEO: Randy Teel
- Employees: 246
- 5 Science Park, New Haven, CT, 06511, US
- www.arvinas.com
Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.
Data from the stock’s TipRanks forecast page, read 66 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗